These benefits occur quickly following treatment initiation, suggesting that GLP-1 medicines may reduce cardiovascular events, at least in part, through weight loss-independent mechanisms
The results, by dose: For context: in the equivalent Phase 2 trials, semaglutide produced about 14.9% weight loss at the highest dose, and tirzepatide produced about 20.9%
6B), consistent with previous observations 16
Under comparable conditions, tirzepatide demonstrates more pronounced weight loss, however, tolerance and concomitant diseases are always considered individually
These results are comparable to surgical interventions learn more about how Retatrutide compares to bariatric surgery in our detailed analysis